[A19-97] Olaparib (breast cancer) - Addendum to Commission A19-57
Last updated 16.01.2020
Project no.:
A19-97
Commission:
Commission awarded on 26.11.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Monotherapy of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer
Result of dossier assessment:
Conclusion of dossier assessment A19-57 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-57 | Olaparib (breast cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-01-16 A G-BA decision was published.